

Alicante, 5<sup>th</sup> of September 2025

**COMMUNICATION- OTHER RELEVANT INFORMATION- FACEPHI BIOMETRIA, S.A.**

Dear Sirs,

Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), and section 4.5.1 of Euronext Growth Markets Rule Book Part I: Harmonized Rules, on ongoing obligations of companies listed on Euronext, (hereinafter “Facephi” or “the Company”) hereby notifies the following:

Facephi and Nice & Green, the Company’s main shareholder, have executed on September 2, 2025, a loan intended to cover working capital needs for a maximum amount of up to 1.500.000 €, of which 1.000.000 € was drawn on the agreement date. The remaining amount, 500.000 €, is available to the Company for use, should it so decide.

The loan accrues variable interest at Euribor 1 month plus 3.50%. The final maturity date is 31 of January 2026, and it entailed a formalization fee of 1.000 €.

The Company highlights that this loan is not convertible into shares and is therefore structured solely and exclusively as repayable financial debt which, moreover, not only does not imply an increase in its indebtedness, but, in fact, as of the date of the loan, it stands at levels even lower than those as of December 31, 2024.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

---

Javier Mira Miró

**Chairman of the Board of Directors**